About Dr. Li Xiaobing
Dr. Li Xiaobing (李晓兵) is a Professor, Doctoral Supervisor, and one of China's experienced medical oncologists, based at the Department of Medical Oncology, Changhai Hospital, Naval Medical University (Second Military Medical University). With extensive clinical expertise in the systemic treatment of solid tumors — including lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, and breast cancer — Dr. Li is recognized as a senior authority in medical oncology at one of China's most distinguished military academic medical centers. His clinical practice encompasses the full spectrum of modern cancer systemic therapy: cytotoxic chemotherapy, targeted therapy, immunotherapy, and the integration of these modalities in multimodal treatment strategies developed through multidisciplinary tumor board review.
Medical oncology has been transformed over the past two decades by the development of molecularly targeted therapies and immune checkpoint inhibitors that have dramatically improved outcomes for patients with many common solid tumors. The optimal selection and sequencing of these agents — based on tumor molecular profiling, biomarker assessment, and the rapidly evolving evidence base from clinical trials — requires a level of specialist expertise and access to current clinical trial data that is available at only a small number of academic medical oncology centers. Dr. Li's clinical practice at Changhai Hospital — supported by the hospital's active clinical trials program and its multidisciplinary tumor board infrastructure — provides international patients with access to the latest evidence-based systemic therapy protocols and, where appropriate, investigational agents through clinical trials.
For international patients — expatriates living in Shanghai and medical tourists from regions where access to the latest targeted therapies and immunotherapy agents is limited or prohibitively expensive — Dr. Li and Changhai Hospital's medical oncology department offer access to the full range of approved systemic cancer therapies at costs substantially below those of equivalent treatment in Western healthcare systems, with access to specialist consultation typically achievable within days through CMCS.
Hospital Affiliation: Department of Medical Oncology, Changhai Hospital
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers. Its Department of Medical Oncology is a high-volume, multidisciplinary oncology program managing the full spectrum of solid tumors, supported by dedicated tumor boards for lung cancer, gastrointestinal cancer, breast cancer, and other major tumor types that integrate medical oncology, surgical oncology, radiation oncology, interventional radiology, and pathology. The department's clinical trials program provides access to investigational systemic therapies — including novel targeted agents, immunotherapy combinations, and antibody-drug conjugates — for patients who have exhausted standard treatment options or who wish to access cutting-edge therapies not yet approved in their home countries.
The department's pharmacy and infusion center provides the full range of intravenous and oral systemic cancer therapies, including cytotoxic chemotherapy regimens, monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, and supportive care medications. Its supportive oncology program integrates palliative care, pain management, nutritional support, and psychological support into the comprehensive cancer care pathway.
Clinical Specialties: What Dr. Li Xiaobing Treats
- Lung cancer — first-line and subsequent-line systemic therapy for non-small cell lung cancer (NSCLC) including EGFR-mutant NSCLC (osimertinib, gefitinib, erlotinib, afatinib), ALK-rearranged NSCLC (alectinib, brigatinib, lorlatinib), ROS1-rearranged NSCLC, BRAF V600E-mutant NSCLC, MET exon 14-skipping NSCLC, RET-rearranged NSCLC, and NTRK-rearranged NSCLC; immunotherapy with pembrolizumab, nivolumab, atezolizumab, and combination chemo-immunotherapy for PD-L1-expressing and wild-type NSCLC; small cell lung cancer (SCLC) chemotherapy and immunotherapy; coordination with thoracic surgery and radiation oncology for multimodal treatment
- Colorectal cancer — first-line and subsequent-line systemic therapy for metastatic colorectal cancer including FOLFOX, FOLFIRI, FOLFOXIRI, and bevacizumab combinations; anti-EGFR therapy (cetuximab, panitumumab) for RAS/BRAF wild-type tumors; BRAF V600E-targeted therapy (encorafenib/cetuximab); immunotherapy with pembrolizumab for MSI-high/dMMR colorectal cancer; TAS-102 and regorafenib for refractory disease; HER2-targeted therapy for HER2-amplified colorectal cancer; coordination with colorectal surgery and radiation oncology for neoadjuvant and adjuvant treatment
- Gastric and gastroesophageal junction cancer — first-line chemotherapy with FLOT, XELOX, or SOX regimens; trastuzumab for HER2-positive gastric cancer; immunotherapy with nivolumab or pembrolizumab for PD-L1-expressing or MSI-high gastric cancer; ramucirumab and paclitaxel for second-line treatment; coordination with gastric surgery and radiation oncology for perioperative and adjuvant treatment
- Pancreatic cancer — first-line chemotherapy with FOLFIRINOX or gemcitabine/nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma; PARP inhibitor maintenance therapy (olaparib) for BRCA-mutant pancreatic cancer; second-line chemotherapy options; coordination with pancreatic surgery for neoadjuvant treatment of borderline resectable disease and adjuvant chemotherapy after resection
- Breast cancer — systemic therapy for early and metastatic breast cancer including hormone receptor-positive (CDK4/6 inhibitors, aromatase inhibitors, fulvestrant), HER2-positive (trastuzumab, pertuzumab, T-DM1, trastuzumab deruxtecan), and triple-negative breast cancer (chemotherapy, immunotherapy, PARP inhibitors for BRCA-mutant disease, sacituzumab govitecan); coordination with breast surgery and radiation oncology for neoadjuvant and adjuvant treatment
- Hepatocellular carcinoma (HCC) — systemic therapy for advanced HCC including sorafenib, lenvatinib, atezolizumab-bevacizumab, sintilimab-bevacizumab, and other approved first-line regimens; second-line options including regorafenib, cabozantinib, and ramucirumab; coordination with hepatobiliary surgery, interventional radiology, and radiation oncology for multimodal HCC management
- Clinical trials access — evaluation of eligibility for investigational systemic therapy clinical trials at Changhai Hospital; access to novel targeted agents, immunotherapy combinations, antibody-drug conjugates, and other investigational therapies not yet approved in China or internationally; coordination with the clinical trials office for enrollment and monitoring
Why International Patients Choose Dr. Li Xiaobing and Changhai Hospital
International patients seek medical oncology consultation with Dr. Li Xiaobing and Changhai Hospital for reasons that reflect both the clinical depth of his expertise and the practical advantages of accessing cancer systemic therapy in Shanghai.
For patients with molecularly targeted cancers — EGFR-mutant lung cancer, HER2-positive breast or gastric cancer, MSI-high colorectal cancer, or BRCA-mutant pancreatic or breast cancer — Dr. Li's expertise in the selection and sequencing of targeted therapies and immunotherapy agents, informed by the latest clinical trial evidence and supported by Changhai Hospital's comprehensive molecular profiling capabilities, provides access to precision oncology treatment that may not be available or affordable in the patient's home country. The cost of targeted therapies and immunotherapy agents at Changhai Hospital is substantially below that of equivalent treatment in Western healthcare systems — a difference that can be clinically decisive for patients whose treatment options are limited by cost.
For patients who have exhausted standard treatment options and are seeking access to investigational therapies, Changhai Hospital's active clinical trials program provides a pathway to novel agents and combinations that are not yet approved in China or internationally. CMCS can coordinate the evaluation of clinical trial eligibility and the enrollment process for international patients.
Access to specialist medical oncology consultation at Changhai Hospital can typically be arranged within days through CMCS, in contrast to the weeks of waiting that are common in public oncology services in many countries.
What to Expect at Your Consultation
Consultations with Dr. Li Xiaobing at Changhai Hospital arranged through CMCS begin with a comprehensive review of all prior oncological records — including pathology reports and molecular profiling results, staging imaging (CT, MRI, PET-CT), tumor marker trends, prior systemic therapy records including regimens, response assessments, and toxicities, and relevant laboratory investigations. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation.
Dr. Li will assess the tumor type, stage, and molecular profile, evaluate current treatment options and their evidence base, outline the recommended systemic therapy strategy with detailed rationale, assess clinical trial eligibility where appropriate, and coordinate multidisciplinary tumor board review. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Li's team and the patient's home oncologist for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking medical oncology consultation with Dr. Li Xiaobing at Changhai Hospital. Our services include priority consultation scheduling, certified medical record and pathology report translation, coordination of molecular profiling and staging investigations, on-site interpretation throughout the consultation, systemic therapy administration coordination and pharmacy support, clinical trial eligibility assessment, and written English-language reporting of all findings and recommendations. CMCS will also facilitate direct communication between Dr. Li's team and the patient's home oncologist to ensure seamless continuity of care.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 則留言